



Diabetes Boot Camp – Class 4

Beverly Dyck Thomassian, RN, MPH, BC-ADM, CDE
President, Diabetes Education Services

www.DiabetesEd.net



Diabetes Meds for Type 2: Objectives



1. Describe the main action of the different categories of type 2 diabetes medications.
2. Discuss strategies to determine the right medication for the right patient.
3. List the side effects and clinical considerations of each category of medication.



© Copyright 1999-2014, Diabetes Educational Services, All Rights Reserved 

Poll question 1

- ▶ When starting patients on medications, what is the most important factor to consider?
 - a. Their level of compliance
 - b. Their diabetes pathology
 - c. Their education level
 - d. Their preferences, needs and values



Poll question 2

- ▶ According to the AACE Glycemic Control Algorithm, what is the first step to control hyperglycemia in type 2?
 - a. Lifestyle modification
 - b. Start insulin
 - c. Start metformin
 - d. Start 2 meds if their A1c is 7.4%



Poll question 3

- ▶ John is started on Metformin 500mg BID. What of the following is true?
- a. Hold metformin if your blood glucose is below 90 mg/dl.
 - b. If you forget to take metformin before the meal, hold the dose.
 - c. Take metformin with meals
 - d. Always hold metformin if you are sick



Diabetes Education
SERVICES

Poll Question 4

- ▶ Which of the following is true about sulfonylureas?
- a. Most patients experience some weight loss
 - b. 50% of patients have no improvement in BG levels
 - c. Do not take with grapefruit juice
 - d. Be aware of signs of hypoglycemia



Diabetes Education
SERVICES

Poll Question 5

- ▶ When goal is to avoid hypoglycemia, which medication class would you recommend?
- a. Meglitinides
 - b. SGLT-2 Inhibitors
 - c. Sulfonylureas
 - d. Analog insulins



Poll Question 6

- ▶ Alice injects exenatide XR (Bydureon) once a week. Which of the following should she report immediately?
- a. Bump at the injection site
 - b. Nausea
 - c. Weight loss
 - d. Sudden abdominal pain



Poll Question 7

- ▶ For patients on SGLT-2 Inhibitors, a potential side effect is:
- Balanitis
 - Hypertension
 - Kidney tenderness
 - Increased uric acid



Diabetes Education
SERVICES

Poll Question 8

- ▶ George type 2, is losing weight and thirsty with an A1c of 10.3%. Using AACE guidelines, what is appropriate action?
- Evaluate lifestyle changes for 3 months
 - Start insulin therapy
 - Start metformin immediately
 - Start metformin plus another agent



Diabetes Education
SERVICES

Diabetes Agents Considerations

- ▶ Diabetes medications can be used as monotherapy, in combo or with insulin
- ▶ Combining agents from different classes has additive effect
- ▶ Most reduce A1c 0.5 – 2.0%
- ▶ Not to be used during preconception, pregnancy or when breastfeeding



Diabetes Education
SERVICES

Patient Centered Approach

“...providing care that is respectful of and responsive to individual patient preferences, needs, and values - ensuring that patient values guide all clinical decisions.”

- Gauge patient’s preferred level of involvement.
- Explore, where possible, therapeutic choices.
- Utilize decision aids.
- **Shared** decision making – final decisions re: lifestyle choices ultimately lie with the patient.



ADA-EASD Position Statement: Management of Hyperglycemia in T2DM


Diabetes Care 2012;35:1364–1379
Diabetologia 2012;55:1577–1596



Diabetes Education
SERVICES

Considerations

- ▶ Cost
- ▶ Hypoglycemia
- ▶ Age
- ▶ Weight
- ▶ Comorbidities
 - ▶ Kidney disease
 - ▶ Heart disease – CHF, CAD
 - ▶ Liver dysfunction



ADA-EASD Position Statement: Management of Hyperglycemia in T2DM

Diabetes Care 2012;35:1364–1379
Diabetologia 2012;55:1577–1596



Diabetes Education
SERVICES

When goal is to minimize cost

- ▶ Go generic. Metformin and Sulfonylureas
- ▶ Walmart offers 3 month supply of following meds for ~ \$10
 - ▶ Metformin and Metformin XR
 - ▶ Glipizide, Glyburide, Glimepiride
- ▶ Other generics include
 - ▶ Actos and Avandia
 - ▶ Acarbose
 - ▶ Can still cost up to \$100 a month
- ▶ Meds on a Budget Article



Diabetes Education
SERVICES

Resources for Medications

- ▶ Partnership for Prescription Assistance
 - ▶ www.pparx.org
- ▶ NeedyMeds.org
- ▶ www.rxassist.org



Diabetes Education
SERVICES

Action/Classes of Type 2 Meds

- | | | |
|------------------------|---|--|
| 1. Suppressor | ➔ | Biguanide – Metformin |
| 2. Squirter | ➔ | Sulfonylureas
Meglitinides |
| 3. Satiators | ➔ | AmylinoMimetics
Incretin Mimetics
DPP-4 Inhibitors |
| 4. Sensitizer | ➔ | Thiazolidinediones (TZD) |
| 5. Glucoretics | ➔ | SGLT2 Inhibitors |
| 6. Circadian Switchers | ➔ | Dopamine Receptor
Agonists |
| 7. Slower | ➔ | Alpha-glucosidase inhibitors |



Diabetes Education
SERVICES

Antihyperglycemic Therapy – 1st Step

- ▶ Lifestyle Changes
 - ▶ Weight control
 - ▶ Healthy eating
 - ▶ Activity




ADA-EASD Position Statement: Management of Hyperglycemia in T2DM

Diabetes Care 2012;35:1364–1379
Diabetologia 2012;55:1577–1596



Diabetes Education SERVICES



LEGEND

✓ Few adverse events or possible benefits ⚠ = Use with caution

Ideal Diabetes Med -




- ▶ No hypoglycemia
- ▶ No weight gain
- ▶ Affordable
- ▶ Lowers CV risk
- ▶ Most people can tolerate /use?



Diabetes Education
SERVICES

Biguanides – Suppressor Metformin (GlucoPhage®)

- ▶ Action: suppresses release of glycogen from the liver
- ▶ Who?
 - ▶ Fasting hyperglycemia
 - ▶ Dysmetabolic Syndrome
 - ▶ For pediatrics starting age 10
 - ▶ (XR age 17)



Glycogen Stopper
and
GLP Enhancer?



Diabetes Education
SERVICES

Biguanides - Metformin

- ▶ **Action:** decrease hepatic glucose (glycogen)
- ▶ **Names:**
 - ▶ Metformin (Glucophage)
 - ▶ Starting dose: 500 BID, max 2500mg daily
 - ▶ Metformin extended release (3 different versions)
 - ▶ Starting dose 500mg at dinner, max dose 2000 to 2500 mg daily
- ▶ **Efficacy:**
 - ▶ Decrease fasting plasma glucose 60-70 mg/dl
 - ▶ Reduce A1C 1.0-2.0%



© Copyright 1999-2014, Diabetes Educational Services, All Rights Reserved

Diabetes Education
SERVICES

Biguanides - Metformin

- ▶ **Benefits**
 - ▶ Decrease LDL cholesterol and triglycerides
 - ▶ No weight gain, possible modest weight loss
 - ▶ Cancer protective?
- ▶ **Concerns**
 - ▶ Diarrhea and abdominal discomfort – Use XR
 - ▶ Lactic acidosis if improperly prescribed
 - ▶ Watch for B12 deficiency
 - ▶ Hold prior to IV contrast dye studies and use caution during acute illness. Resume when kidney function adequate



Diabetes Education
SERVICES

Considerations

Biguanide - Metformin (Glucophage®)

▶ Contraindications due to lactic acidosis:

- ▶ creatinine >1.4 females, >1.5 males
- ▶ liver disease
- ▶ alcohol abuse
- ▶ over 80 years old
- ▶ risk of acidosis
- ▶ during IV dye study
- ▶ CHF requiring meds



Diabetes Education
SERVICES

Metformin – How does it rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?



Diabetes Education
SERVICES

Sulfonylureas –

- ▶ Action: tells pancreas to squirt insulin all day
- ▶ Who?
 - ▶ Lean type 2



Diabetes Education
SERVICES

Sulfonylureas - Squirts

- ▶ Action: Increase endogenous insulin secretion
- ▶ Efficacy:
 - ▶ Decrease FPG 60-70 mg/dl
 - ▶ Reduce A1C by 1.0-2.0%
- ▶ Secondary failures: 5-10% shortly after initial response, many more later
 - ▶ Usually after 5 or more years of therapy due to natural history of DM 2



Diabetes Education
SERVICES

Sulfonylureas: 2nd Generation

<u>Generic</u>	<u>Trade</u>	<u>Duration</u>
▶ Glyburide	Diabeta, Micronase, most likely to cause hypo – last choice	12-24 hrs
▶ Glipizide*	Glucotrol, Glucotrol XI	12-24 hrs
▶ Glimepiride	Amaryl	16-24 hrs



Diabetes Education
SERVICES

Sulfonylureas

- ▶ Other Effects
 - ▶ Hypoglycemia
 - ▶ Weight gain
 - ▶ Cleared by kidney, use caution for pts with kidney problems
 - ▶ Generally the least expensive class of medication
 - ▶ Amaryl safest for those with CV Disease



Diabetes Education
SERVICES

Indication for “Fast Acting” Insulin Secretagogues- Meglitinides

- ▶ Action: tells pancreas to squirt insulin with meals
- ▶ Who?
 - ▶ Targets post-prandial hyperglycemia



Diabetes Education
SERVICES

Meglitinides - Squirts

- ▶ **Action:** stimulate insulin secretion (rapid and short duration) when glucose present
- ▶ **Names:**
 - ▶ repaglinide (Prandin)
 - ▶ **Dosing:** 0.5 to 4 mg a.c. Max dose 16mg
 - ▶ Metabolized by liver and mostly excreted in feces (some renally).
 - ▶ nateglinide (Starlix)
 - ▶ **Dosing:** 120 mg tid with meals
 - ▶ Metabolized by liver, excreted by kidney
- ▶ **Efficacy:**
 - ▶ Decreases peak postprandial glucose
 - ▶ Decreases plasma glucose 60-70 mg/dl
 - ▶ Reduce A1C 1.0-2.0%



Diabetes Education
SERVICES

Meglitinides

- ▶ Other Effects
 - ▶ Hypoglycemia (less than with sulfonylureas if patient has a variable eating schedule)
 - ▶ Minimal weight gain
 - ▶ No significant effect on plasma lipid levels
 - ▶ Safe at higher levels of serum Cr than sulfonylureas



Squirters – How does they rate?

<u>Question</u>	<u>Answer</u>
-----------------	---------------

- | | |
|---------------------------|--|
| ▶ Cause hypoglycemia? | |
| ▶ Cause weight gain? | |
| ▶ Affordable? | |
| ▶ Lowers CV risk? | |
| ▶ Can most tolerate /use? | |



What questions?

- ▶ 72 yr old, thin, lives alone, A1c 7.3%. History of MI, stroke. DM for 12 yrs, “diet controlled”. Limited income. Creat 1.4.



Diabetes Education
SERVICES

Older Adults - Considerations



- Reduced life expectancy
- Higher CVD burden
- Reduced GFR
- At risk for adverse events from polypharmacy
- More likely to be compromised from hypoglycemia



- ✓ Less ambitious targets
- ✓ A1c <7.5–8.0%
- ✓ Focus on drug safety

Diabetes Care 2012;35:1364–1379
Diabetologia
2012;55:1577–1596



© Copyright 1999-2014, Diabetes Educational Services, All Rights Reserved.

Diabetes Education
SERVICES

When goal is to avoid Hypoglycemia

- ▶ Avoid sulfonylureas
- ▶ Careful insulin dosing
- ▶ May need to up adjust glucose goals
- ▶ Monitor kidney function
- ▶ Reinforce for patients on insulin to “TIE”
 - ▶ Test
 - ▶ Inject
 - ▶ Eat



Diabetes Education
SERVICES

DPP-4 Inhibitors – “Incretin Enhancers”

Januvia (sitagliptin) – Tradjenta (linagliptin)

Onglyza (saxagliptin) Nesina (alogliptin)

- ▶ **Action:**
 - ▶ Increase insulin release w/ meals
 - ▶ Suppress glucagon
- ▶ **Dosing:** Januvia – 100mg a day
 Onglyza – up to 5mg a day
 Tradjenta – 5mg a day
 Nesina – up to 25 mg a day
- ▶ **Efficacy:** Decreases A1c by 0.6 -0.8%
- ▶ **Indication:** For type 2s



Diabetes Education
SERVICES

DPP-4 Inhibitors – “Incretin Enhancers”

Januvia (sitagliptin) – Tradjenta (linagliptin)
Onglyza (saxagliptin) Nesina (alogliptin)

- ▶ Januvia, Onglyza eliminated via kidney, lower dose needed
- ▶ Do not cause wt gain or hypoglycemia
- ▶ Side effects – headache, runny nose, sore throat - watch for pancreatitis
- ▶ Cost \$100 - \$150 mo



Diabetes Education
SERVICES

DPP-IV Inhibitors – How do they rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?



Diabetes Education
SERVICES

If on Metformin and Sulfonylurea – A1c 8.4 - Pt struggling with weight



Diabetes Education
SERVICES

When goal is to avoid weight gain

- ▶ These meds are weight neutral
 - ▶ Metformin
 - ▶ DPP-IV Janvia, Onglyza, Tradjenta, Nesina
 - ▶ Acarbose


- ▶ These meds associated with wt loss
 - ▶ GLP-1 agonists (Byetta, Bydureon, Victoza, Tanzeum)
 - ▶ SGLT-2 Inhibitors (Canagliflozin, Dapagliflozin)
 - ▶ Symlin (Pramlintide)



Diabetes Education
SERVICES


Incretin Mimetics – “Gut Hormone Imitators” GLP-1 Agonists

▶ How do they work?



Diabetes Education SERVICES

GLP-1 Effects in Humans Understanding the Natural Role of Incretins



Adapted from Flint A, et al. *J Clin Invest.* 1998;101:515-520
Adapted from Larsson H, et al. *Acta Physiol Scand.* 1997;160:413-422
Adapted from Nauck MA, et al. *Diabetologia.* 1996;39:1546-1553
Adapted from Drucker DJ. *Diabetes.* 1998;47:159-169

GLP-1 degraded by DPP-4 w/in minutes



Diabetes Education SERVICES

Weight Considerations



- Majority of T2DM patients overweight / obese
- Intensive lifestyle program
- Metformin
- GLP-1 receptor agonists
- ? Bariatric surgery
- Consider LADA in lean patients

Diabetes Care 2012;35:1364-1379
Diabetologia
2012;55:1577-1596

ADA-EASD Position Statement: Management of Hyperglycemia in T2DM



Diabetes Education
SERVICES

Incretin Mimetics

Exenatide (Byetta), Exenatide XR (Bydureon)

▶ Action:

- ▶ Insulin release in response to meal
- ▶ Slows gastric emptying
- ▶ Causes Satiety
- ▶ Protects Beta Cells

▶ Exenatide Dosing:

- ▶ 5-10 mcg before break, dinner
- ▶ Long acting version - 1x week (available in pens in 2015)

▶ Efficacy: Decreases A1c by 0.7%, wt by 3lbs

▶ Indication: For type 2s only - mono or in combo



Diabetes Education
SERVICES

Incretin Mimetics - GLP-1 Analog

Liraglutide (Victoza)

Liraglutide Dosing: 1x daily, time not critical

- 0.6 x 1 week – if tolerated (nausea), go to >
- 1.2 x 1 week – if tolerated go to >
- 1.8 mg daily
- ▶ **Efficacy:** lowers; A1c by 1%, body wt by ~ 2.5kg
- ▶ **Indication:** Monotherapy or in combo . Type 2 only
- ▶ **Other:** In pen, with preset dosing
- ▶ **Black box**–thyroid tumor warning (avoid if family hx, notify MD of hoarseness, lump).



Diabetes Education
SERVICES

Incretin Mimetics – Exenatide XR - Bydureon


- ▶ **Once a Week Dosing:** 2mg
- ▶ **Efficacy:** Decreases A1c by 1.6%, wt by ~6lbs
- ▶ **Indication:** For type 2s only
- ▶ **Other:** Pt will need to mix powdered form and inject
– Pen in future
- ▶ **Caution:**
 - ▶ not indicated for those with history of medullary thyroid tumor
 - ▶ pancreatitis warning



Diabetes Education
SERVICES

Incretin Mimetics – Albiglutide - Tanzeum

- ▶ **Once a Week Dosing:** 30 – 50mg
- ▶ **Efficacy:**
Decreases A1c by ~ 1%, wt by ~2lbs
- ▶ **Indication:** For type 2s only
- ▶ **Other:** Pen injector
- ▶ **Caution:** not indicated for those with history of medullary thyroid tumor - pancreatitis warning



Diabetes Education
SERVICES

Incretin Mimetics – dulaglutide – Trulicity

- ▶ **Once a Week Dosing:** 0.75 – 1.5 mg
- ▶ **Efficacy:**
Decreases A1c by ~ 1%, wt by ~2lbs
- ▶ **Indication:** For type 2s only
- ▶ **Other:** Premixed Pen injector with retracting needle
- ▶ **Caution:** not indicated for those with history of medullary thyroid tumor - pancreatitis warning



Diabetes Education
SERVICES

For all the Previous GLP-1 Agonists

- Pancreatitis

Warning

- Please tell all patients to report signs right away and discontinue meds
- Signs include:
- Sudden abdominal pain, nausea and vomiting



Diabetes Education
SERVICES

Incretin Mimetics – How do they rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?



Diabetes Education
SERVICES

Considerations



- May temporarily lower GFR
- Monitor B/P, K⁺ & renal function.
- Side effects: hypotension, UTI, increased urination, genital yeast infections.
- Other benefits?
 - Reverses glucose toxicity by increasing GLUT4 transport in muscle
 - Increase liver sensitivity to insulin and decreases gluconeogenesis.



Diabetes Education
SERVICES

SGLT2 Inhibitors- How do they rate?

Question	Answer
▶ Cause hypoglycemia?	No
▶ Cause weight gain?	No
▶ Affordable?	No
▶ Lowers CV risk?	No
▶ Can most tolerate /use?	Yes?



Diabetes Education
SERVICES

Indications for Insulin Sensitizers

Rosiglitazone (Avandia), Pioglitazone (Actos)

- ▶ **Action:** decrease insulin resistance by making muscle and adipose cells more sensitive to insulin. Decrease free fatty acids
- ▶ **Names:**
 - ▶ pioglitazone (Actos) – bladder cancer warning
 - ▶ Dosing: 15-45 mg daily
 - ▶ rosiglitazone (Avandia) – restriction relaxed
 - ▶ Dosing: 4-8 mg daily
- ▶ **Efficacy/ Considerations**
 - ▶ Reduce A1C ~0.5-1.0%
 - ▶ 6 weeks for maximum effect
 - ▶ \$100 a month
 - ▶ Can cause fluid retention, not indicated w/ CHF



Diabetes Education
SERVICES

TZDs – How do they rate?

<u>Question</u>	<u>Answer</u>
-----------------	---------------

- | | |
|---------------------------|--|
| ▶ Cause hypoglycemia? | |
| ▶ Cause weight gain? | |
| ▶ Affordable? | |
| ▶ Lowers CV risk? | |
| ▶ Can most tolerate /use? | |



Diabetes Education
SERVICES

Indications for Glucosidase Inhibitors Acarbose (Precose®), Miglitol (Glyset®)

Action: Slower

- ▶ Target post-prandial blood glucose
- ▶ Minimal systemic absorption



Diabetes Education
SERVICES

Alpha-glucosidase Inhibitors

- ▶ **Action:** blocks enzymes that digest starches in the small intestine
- ▶ **Name:** acarbose (Precose)
 - ▶ Dosing: 75-300mg based on weight
- ▶ **Efficacy**
 - ▶ Decrease postprandial glucose 40-50 mg/dl
 - ▶ Decrease A1C 0.5-1.0%
- ▶ **Other Effects**
 - ▶ Flatulence or abdominal discomfort
 - ▶ Contraindicated in patients with inflammatory bowel disease or cirrhosis
- ▶ **Special Consideration**
 - ▶ In case of hypoglycemia, treat with glucose tabs or milk
 - ▶ (other starches are blocked by medication))



Diabetes Education
SERVICES

Acarbose– How does it rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?



Diabetes Education
SERVICES

Critical Points

- ▶ Individualize Glycemic targets & BG-lowering
- ▶ Diet, exercise, & education: foundation T2DM therapy
- ▶ Metformin = optimal 1st-line drug.
- ▶ After metformin, data limited. Combo therapy reasonable
- ▶ Ultimately, many T2 patients will require insulin therapy
- ▶ All treatment decisions should be made in conjunction with the patient (focus on preferences, needs & values.)
- ▶ CV risk reduction - a major focus of therapy.

ADA-EASD Position Statement: Management of
Hyperglycemia in T2DM

Diabetes Care 2012;35:1364–1379
Diabetologia 2012;55:1577–1596



Diabetes Education
SERVICES

 **PROFILES OF ANTIDIABETIC MEDICATIONS**

	MET	DPP-4i	GLP-1 RA	TZD	AGI	COLSVL	BCR-QR	SU GLN	INSULIN	SGLT-2	PRAML
HYPO	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate/ Severe Mild	Moderate to Severe	Neutral	Neutral
WEIGHT	Slight Loss	Neutral	Loss	Gain	Neutral	Neutral	Neutral	Gain	Gain	Loss	Loss
RENAL/ GU	Contra- indicated Stage 3B,4,5	Dose Adjustment May be Necessary (Except Linagliptin)	Exenatide Contra- indicated CrCl < 30	May Worsen Fluid Retention	Neutral	Neutral	Neutral	More Hypo Risk	More Hypo Risk & Fluid Retention	Infections	Neutral
GI Sx	Moderate	Neutral	Moderate	Neutral	Moderate	Mild	Moderate	Neutral	Neutral	Neutral	Moderate
CHF	Neutral	Neutral	Neutral	Moderate	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral
CVD	Benefit			Neutral			Safe	?			
BONE	Neutral	Neutral	Neutral	Moderate Bone Loss	Neutral	Neutral	Neutral	Neutral	Neutral	? Bone Loss	Neutral

Few adverse events or possible benefits
 Use with caution
 Likelihood of adverse effects

Copyright © 2013 AAACE. May not be reproduced in any form without express written permission from AAACE.

Self Sudy - List the Treatment Options

- ▶ 35 yr old, BMI 28, creat 0.8, A1c 6.7%
 Sit 1: Wants to try lifestyle changes before meds
 Sit 2: Started on Januvia, can't afford it. What alt med?
- ▶ 72 yr old, thin, lives alone, A1c 7.3%. History of MI, stroke.
 On glyburide 10mg a day and beta blocker. Creat 1.4.
- ▶ 69 year old male, BMI 25, on Metformin 1000mg BID. AM
 glucose 120s, A1c 8.1%. Creat 1.3
- ▶ 64 yr old on daily; amaryl 4mg, Januvia 100mg, Avandia® 4
 mg. A1c 9.2%. Pt c/o of 12 lb wt gain over past month.
 Creat 1.2, LDL 138
- ▶ Pt on Exenatide 10mcg BID, c/o of sudden abd pain.



Thank You



Diabetes Education
SERVICES